Polymeric Inhibitors of Mannose Receptor.

A novel polymers to provide a potential treatment option for IRI and other inflammatory conditions

AboutUniversity of Nottingham
The University of Nottingham produces world-changing research by focussing on the problems and challenges that affect societies and people on a wide scale. More than 80% of Nottingham research is ranked in the highest categories ‘world-leading’ or ‘internationally excellent’.


Blockage/inhibition of Mannose Receptor (MR) can allow the modulation of immune responses and inflammation. Dampening down the inflammatory response is needed in many disease states including atherosclerosis, chronic obstructive pulmonary disease (COPD), cancer and ischaemia reperfusion injury (IRI). However, the potential of MR as a therapeutic clinical target has yet to be clinically exploited. The researchers have found a molecular pathway that appears to be critical in IRI, and a novel means of downregulating it using the customised polymers.

Make An Enquiry.